This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with prostate cancer. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
This guideline includes new and updated recommendations on:
- MRI and biopsy
- localised and locally advanced prostate cancer
- follow-up for localised or locally advanced prostate cancer
- treatment for metastatic prostate cancer
- bone-targeted therapies
It also includes recommendations on:
Who is it for?
- Healthcare professionals
- Commissioners and providers of prostate cancer services
- People with prostate cancer, their families and carers
Is this guideline up to date?
We checked this guideline in February 2021 in response to new evidence from a nationwide cohort study on predicting prostate cancer death with different pretreatment risk stratification tools and the National Prostate Cancer Audit: prostate biopsy short report. We plan to update recommendation 1.2.16 on risk stratification and to consider the impact of changes to risk stratification on treatment recommendations.
Guideline development process
This guideline updates and replaces NICE guideline CG175 (January 2014) and NICE diagnostics guidance 17 (June 2015).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.